Initio Parfums Privés has backed a new research project that aims to help people affected by olfactory disorders.
The French functional fragrance brand has partnered with the Versailles Hospital and Université Paris Cité to support research into the health issue, alongside Dr Hakim Benkhatar, an ENT physician and scientific expert in olfaction.
Nearly a quarter of the global population is thought to be affected by olfactory disorders, with 5% suffering from a complete loss of sense of smell, known as anosmia.
Initio will support the Single Molecule Olfactory Testing and Training (SMOTT) project, a three-year research programme aimed at transforming the management of these types of disorders.
It is estimated that around 40% of those affected by olfactory health issues experience depressive symptoms.
Initio hopes to actively contribute to accelerating scientific research through its support of SMOTT, as well as developing innovative tools for healthcare professionals and providing more effective solutions for patients.
“This partnership is about more than fragrance,” the company said in a statement.
“It focuses on supporting wellbeing, strengthening connection, and restoring an important part of the human experience.
“Our sense of smell plays a key role in memory and relationships.
“By investing in the SMOTT project, Initio is supporting meaningful research and giving back to the community in a practical way.
“The objective is for the research outcomes to contribute to global clinical understanding and to be relevant for practitioners beyond France.”